At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 24 enrolled
Drug / intervention
Doxycyclinedrug
Likely dose
Doxycycline 100mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Daily Doxy: Study of Persons Receiving Daily Doxycycline to Inform Sexually Transmitted Infection Prophylaxis Regimens
In Brief
A Phase 4 clinical trial evaluating Doxycycline for Sexually Transmitted Infection. Completed, enrolled 24 participants across 1 site.
Detailed Summary
The goal of this project is to collect data regarding the concentrations of doxycycline in mucosal tissues after daily dosing for 7 days in people assigned male sex at birth (AMAB) and assigned female sex at birth (AFAB) to inform future studies of doxycycline to protect against bacterial sexually transmitted infections (STIs).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSexually Transmitted Infection
CountriesUnited States
CollaboratorsCenters for Disease Control and Prevention
Timeline
Phase 4CompletedFinished
20252026
First PostedAug 2024
Enrollment StartSep 2024
Primary CompletionApr 2025
TodayJul 2026
First PostedAug 9, 2024
Enrollment StartSep 13, 2024
Primary CompletionApr 29, 2025
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 1.9 years ago
Interventions
Doxycyclinedrug
Doxycycline (DOX) will be given orally at 100mg doses. Participants will take the study medication for 7 consecutive days.